I: Treatment of endometriosis, benign breast disorders i.e., mastalgia and fibrocystic breast disease, gynaecomastia, menorrhagia associated with dysfunctional uterine bleeding, and prevention of hereditary angioedema.
D: In women of child-bearing potential treatment should start during menstruation preferably on day 1. Endometriosis: 200-800 mg daily in up to 4 divided doses usually for 3-6 months. Severe pain and tenderness in benign fibrocystic breast disease: 300 mg daily in divided doses usually for 3-6 months. Hereditary angioedema: Initially 200 mg 2-3 times daily, then reduced according to response. Or as prescribed by the physician.
CI: Undiagnosed abnormal genital bleeding. Markedly impaired hepatic, renal or cardiac function, porphyria, lactation.
P: Monitor patients for signs of androgenic effects some of which may not be reversible even when drug administration is stopped. Perform periodic liver function tests. Pregnancy. Pregnancy Risk Category X.
SE: Androgen like effects such as, weight gain, acne and seborrhea. Mild hirsutism, edema, hair loss, voice change. Menstrual disturbances such as, spotting, alteration of the timing of the cycle and amenorrhea. Rushing, sweating, vaginal dryness, irritation and reduction in breast size. Abnormalities in semen volume, viscosity, sperm count, motility.
DI: Warfarin, carbamazepine.
Pr: Cap 200 mg x 100's
DR-XY32951 2017-02-02 200 mg
Write a review
Note: HTML is not translated!
Rating: Bad Good
Enter the code in the box below: